Real-World Evidence Study on the Long-Term Safety of Everolimus in Patients With Tuberous Sclerosis Complex: Final Analysis Results.

MLA

Ruiz-Falcó Rojas, María Luz, et al. “Real-World Evidence Study on the Long-Term Safety of Everolimus in Patients With Tuberous Sclerosis Complex: Final Analysis Results.” Frontiers in Pharmacology, vol. 13, Apr. 2022, p. 802334. EBSCOhost, https://doi.org/10.3389/fphar.2022.802334.

APA

Ruiz-Falcó Rojas, M. L., Feucht, M., Macaya, A., Wilken, B., Hahn, A., Maamari, R., Hirschberg, Y., Ridolfi, A., & Kingswood, J. C. (2022). Real-World Evidence Study on the Long-Term Safety of Everolimus in Patients With Tuberous Sclerosis Complex: Final Analysis Results. Frontiers in Pharmacology, 13, 802334. https://doi.org/10.3389/fphar.2022.802334

Chicago

Ruiz-Falcó Rojas, María Luz, Martha Feucht, Alfons Macaya, Bernd Wilken, Andreas Hahn, Ricardo Maamari, Yulia Hirschberg, Antonia Ridolfi, and John Chris Kingswood. 2022. “Real-World Evidence Study on the Long-Term Safety of Everolimus in Patients With Tuberous Sclerosis Complex: Final Analysis Results.” Frontiers in Pharmacology 13 (April): 802334. doi:10.3389/fphar.2022.802334.